@FattyNoNatty's loaded body-recomp stack: Reta + BPC/KPV/TB repair cocktail + HGH + HCG + Melanotan 2
That's pretty much the stack Reta, the repair stack (BPC, KVP, TB I consider one cocktail), HGH, HCG, and Melanotan 2 I'll still play with others- but I really don't expect anything to have a real impact like these have
A loaded body-recomp stack from a clearly experienced operator. Retatrutide for fat loss, HGH for the lean-mass envelope, HCG suggesting AAS or TRT in the background, plus the BPC/TB-500/KPV repair cocktail. Mechanism is real, but three things hold it back: retatrutide can't be legitimately sourced outside trials, sustained HGH at recreational doses carries insulin/cardiac/IGF-1 risks the casual framing skips, and 'that's pretty much the stack' isn't accompanied by any bloodwork. The handle 'FattyNoNatty' is more honest than most peptide accounts.
| Goal | Score | Grade | Weight | Why |
|---|---|---|---|---|
| Longevity | — | Not targeted | — | Sustained HGH at body-comp doses elevates IGF-1, which is arguably anti-longevity per the GH/IGF-1/aging literature. The stack isn't framed as longevity, and it isn't built that way. |
| Cognition | — | Not targeted | — | No ingredient with a primary cognitive mechanism. |
| Sleep & recovery | 75 | C | 20% | BPC-157 + TB-500 + KPV is a coherent recovery cocktail and HGH supports tissue repair. Without doses or sleep architecture data, the evidence remains anecdotal. |
| Energy & metabolism | 74 | C | 25% | Retatrutide's triple agonism is metabolically targeted. HGH affects glucose and lipids, and can worsen insulin sensitivity at sustained recreational doses. |
| Body recomposition | 82 | B- | 55% | Real mechanism, experienced operator, known-effective compounds. Held back by undisclosed doses, retatrutide sourcing, and the implied AAS/TRT background that isn't being analyzed openly. |
Ingredients (7)
Retatrutide
Retatrutide on peptidelist.org ↗
- Dose
- unspecified
- Mechanism
- GLP-1 / GIP / glucagon triple-receptor agonist; activates appetite/gastric-emptying (GLP-1), insulin response and lipid metabolism (GIP), and energy expenditure / lipolysis (glucagon) pathways. Eli Lilly trial drug; Phase 2 data exceeded tirzepatide and semaglutide on bodyweight outcomes.
- Take
- Author calls it 'Reta' and gives no dose. Phase 2 trials titrated to 8–12mg/week subQ. Clinical body-comp data is the strongest in the GLP-1-class pipeline. The structural problem isn't the dose. It's that retatrutide is Phase 3 trial-stage with no legitimate civilian supply. Anything from a research-peptide vendor is gray-market diversion or unverifiable counterfeit, and counterfeit GLP-1-class drugs have been documented with off-target compounds.
BPC-157
- Dose
- unspecified
- Mechanism
- Pentadecapeptide derived from a gastric protein; preclinical evidence for angiogenesis, fibroblast migration, and growth-factor signaling. No published human RCTs.
- Take
- Bundled into 'the repair stack' alongside TB-500 and KPV. Standard research-vendor protocol is 200–500mcg/day subQ. As recovery support in a heavy training context (which this stack implies), it's a reasonable inclusion. As the headline anti-injury compound, it's overstated. Author doesn't disclose dose or duration.
KPV
- Dose
- unspecified
- Mechanism
- C-terminal tripeptide of α-MSH; preclinical evidence for anti-inflammatory effects, particularly in murine models of inflammatory bowel disease.
- Take
- Author wrote 'KVP' (a typo for KPV, the C-terminal tripeptide of α-MSH). Dosed in this 'repair cocktail' alongside BPC and TB-500. KPV's strongest preclinical case is anti-inflammatory effects in IBD models. Bundling it into a body-recomp recovery stack is a stretch beyond its actual evidence base. No dose disclosed.
TB-500
- Dose
- unspecified
- Mechanism
- Synthetic fragment of thymosin beta-4; preclinical evidence for actin-binding effects on cell motility and tissue repair. No human trials in this indication.
- Take
- Standard partner to BPC-157 in recovery stacks. Enthusiast loading-phase protocols use 2–5mg/week. As with the other two repair-cocktail components, mechanism is plausible but human evidence is anecdotal and dose-disclosure is absent.
HGH
- Dose
- unspecified
- Mechanism
- Recombinant human growth hormone; activates GH receptor signaling, drives hepatic IGF-1 production, increases lipolysis, supports lean tissue accretion, affects glucose homeostasis. Body-comp effects at supraphysiologic doses are well-characterized.
- Take
- Author doesn't state a dose. Bodybuilding-territory protocols use 2–6 IU/day. Therapeutic GH replacement (for documented adult-onset GH deficiency) is an order of magnitude lower at ~0.2–0.5 IU/day. The casual framing here ignores that sustained HGH at body-comp doses meaningfully accelerates IGF-1-mediated cell-growth pathways with cancer-progression concerns, and frequently induces glucose intolerance, joint stiffness, and water retention. Bloodwork (IGF-1, fasting glucose, HbA1c) is non-optional. The post mentions none.
HCG
- Dose
- unspecified
- Mechanism
- Mimics LH at testicular Leydig cell receptors, stimulating endogenous testosterone production and maintaining testicular volume during HPG-axis suppression from exogenous androgens.
- Take
- Standard adjunct to AAS or TRT to preserve testicular function and fertility. Typical protocol is 250–500 IU 2–3×/week subQ. The presence of HCG in this stack strongly implies exogenous androgens elsewhere. HCG without testosterone is unusual outside fertility contexts. The author's omission of what HCG is supporting against is the single most informative gap in the post.
Melanotan 2
Melanotan 2 on peptidelist.org ↗
- Dose
- unspecified
- Mechanism
- α-MSH analog activating melanocortin receptors: MC1R for melanogenesis (skin pigmentation independent of UV), MC4R for appetite suppression and sexual function. Synthetic, not FDA-approved.
- Take
- Used recreationally for cosmetic tanning. Appetite suppression and libido effects via MC4R are common. Common protocols use 250–500mcg subQ daily during loading, then maintenance. Real concerns: accelerated growth of existing nevi (moles) requiring dermatology surveillance, occasional priapism, nausea, blood-pressure changes. Not FDA-approved anywhere. The body-comp role here is incidental, since retatrutide already covers the appetite axis.
Risks & interactions
- Retatrutide is not legally available outside Eli Lilly trialscritical
Phase 3 trial-stage drug with no legitimate civilian supply chain. Anything sold as 'retatrutide' on the research-peptide market is gray-market diversion or unverifiable synthesis. Counterfeit GLP-1-class drugs have been documented with off-target compounds, including dangerous sympathomimetics. This isn't sourcing risk on top of a legitimate compound. It's the central risk of including retatrutide at all.
- HGH at body-comp doses without disclosed bloodworkhigh
Sustained recreational HGH (2–6 IU/day range) elevates IGF-1 substantially. Known associations: insulin resistance and glucose intolerance, joint stiffness and carpal tunnel symptoms, fluid retention, cardiac structural changes with long-term use, and theoretical cancer-progression risk via IGF-1 in users with undiagnosed neoplasms. IGF-1, fasting glucose, and HbA1c should be tracked quarterly at minimum. The post mentions no monitoring at all.
- HCG inclusion implies undisclosed exogenous androgenshigh
HCG without exogenous testosterone or AAS is unusual outside fertility-restoration contexts. Its inclusion here strongly suggests testosterone or AAS is also being run. The most useful information about the stack (which androgens, what doses, what cycle length) is precisely what's been omitted from the post. A stack analysis without that context is necessarily incomplete.
- Melanotan 2 nevi/melanoma surveillancemedium
MC1R activation accelerates melanogenesis in existing moles. Users with significant nevi history, family melanoma history, or atypical-mole syndrome shouldn't freelance Melanotan 2. Everyone using it should be on annual dermatology surveillance. The risk isn't uniform across dose ranges, but it's real for sustained use.
- GLP-1 / triple-agonist GI side effectsmedium
Retatrutide and other triple agonists cause significant nausea, vomiting, and GI distress in 30%+ of users at therapeutic doses. Slow titration is standard in trial settings. Vendor-sourced retatrutide users typically don't have the protocol structure to titrate cleanly.
- No doses across a 7-compound protocolmedium
Seven active compounds with zero dose disclosure makes the stack not replicable, not titrable, and not safety-evaluable. For a protocol involving HGH, HCG, retatrutide, and an implied AAS/TRT background, this is the wrong level of detail to publish, both for the author and for any reader.
A 7-compound stack including HGH and HCG with no monitoring is a Lambo with no speedometer. IGF-1 trajectory is the single most informative number for this protocol. Fasting glucose and HbA1c catch HGH-driven insulin resistance early. Lipids and hematocrit catch the AAS/TRT side effects this stack implies. The author appears experienced enough to know this. Adding the labs is the highest-value, lowest-cost edit available.
Estimated cost
Retatrutide is the wide variable ($300–1500+ if sourceable, with major caveat that it isn't legitimately available); HGH at compounding-pharmacy prices runs $300–800/mo for 2–4 IU/day; HCG $50–150/mo; the BPC-157/TB-500/KPV repair cocktail $80–150/mo from research-peptide vendors; Melanotan 2 $30–60/mo. Doesn't include any implied AAS/TRT background.